News from rigel pharmaceuticals, inc. A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

( NASDAQ-NMS:JAZZ)

Nov 03, 2009, 07:00 ET

Rigel Announces Third Quarter 2009 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the third quarter and nine months ended September 30,...

Oct 28, 2009, 07:30 ET

Rigel Announces Presentations at Two Investor Conferences

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, chairman and chief executive officer, and Raul R. Rodriguez,...

Oct 16, 2009, 07:30 ET

Rigel to Webcast Analyst Briefing on October 20, 2009

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will webcast its analyst briefing on October 20, 2009 from 4:00-5:00pm EDT...

Sep 17, 2009, 09:19 ET

Rigel Announces Pricing of Public Offering of 13,000,000 Shares of Common Stock

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the pricing of an underwritten public offering of 13,000,000 shares of its common...

Sep 16, 2009, 16:00 ET

Rigel Announces Proposed Offering of 6,000,000 Shares of Common Stock

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it is offering to sell, subject to market and other conditions, 6,000,000 shares...

Aug 04, 2009, 07:30 ET

Rigel Announces Second Quarter 2009 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the second quarter and six months ended June 30, 2009. For...

Jul 23, 2009, 18:00 ET

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that in the TASKi3 Phase 2b clinical trial in rheumatoid arthritis (RA) patients who...

Jul 23, 2009, 12:00 ET

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company plans to host a conference call on Thursday, July 23, 2009 at 7:00...

Jul 09, 2009, 06:00 ET

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R788 (fostamatinib disodium) produced significant clinical improvement in...

Jul 08, 2009, 21:00 ET

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that the Company plans to host a conference call on Thursday, July 9, 2009 at 8:00 am...

Jun 10, 2009, 07:30 ET

Rigel to Present at Jefferies Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled...

Jun 01, 2009, 07:30 ET

Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that its oral Syk inhibitor, R788, is being evaluated in a Phase 2 clinical trial...

May 13, 2009, 07:30 ET

Rigel to Present at JMP Securities Research Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled...

May 05, 2009, 07:00 ET

Rigel Announces First Quarter 2009 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the first quarter ended March 31, 2009. For the first quarter of...

Mar 27, 2009, 07:30 ET

Rigel to Present at Citi's Biotech Day

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled...

Mar 13, 2009, 07:30 ET

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

Preclinical Rationale for Clinical Trial Presented at USCAP Meeting Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced the enrollment of...

Mar 12, 2009, 07:30 ET

Rigel to Present at Keystone Symposia Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it will be presenting at the Keystone Symposia conference on Extrinsic Control of...

Mar 06, 2009, 07:30 ET

Rigel to Present at Barclays Capital Healthcare Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Ryan Maynard, the company's vice president and chief financial officer, is...

Feb 24, 2009, 06:00 ET

Rigel Announces Fourth Quarter and Year End 2008 Financial Results

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today reported financial results for the fourth quarter and year ended December 31, 2008. For...

Feb 05, 2009, 07:30 ET

Rigel to Present at BIO CEO & Investor Conference

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that James M. Gower, the company's chairman and chief executive officer, is scheduled...